Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial
Introduction Standard premedication for paclitaxel-based chemotherapy includes dexamethasone and an histamine 1-antagonist to prevent hypersensitivity reactions (HSRs). However, the pharmacological rationale for dexamethasone is limited, and its use is associated with adverse effects such as hypergl...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2025-04-01
|
| سلاسل: | BMJ Open |
| الوصول للمادة أونلاين: | https://bmjopen.bmj.com/content/15/4/e102770.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|